研究者
J-GLOBAL ID:202201017072281854
更新日: 2024年06月25日 倉田 遊
クラタ ユウ | Kurata Yu
- Yu Kurata, Masaomi Nangaku. Use of antibiotics as a therapeutic approach to prevent AKI-to-CKD progression. Kidney international. 2023. 104. 3. 418-420
- Tomotaka Yamazaki, Imari Mimura, Yu Kurata, Tetsuhiro Tanaka, Masaomi Nangaku. Dznep, a histone modification inhibitor, inhibits HIF1α binding to TIMP2 gene and suppresses TIMP2 expression under hypoxia. Physiological reports. 2023. 11. 17. e15810
- Rika Miura, Imari Mimura, Hanako Saigusa, Tomotaka Yamazaki, Fumiaki Tanemoto, Yu Kurata, Dai Sato, Tetsuhiro Tanaka, Masaomi Nangaku. Chromatin remodeling factor, INO80, inhibits PMAIP1 in renal tubular cells via exchange of histone variant H2A.Z. for H2A. Scientific reports. 2023. 13. 1. 13235-13235
- Hanako Saigusa, Imari Mimura, Yu Kurata, Tetsuhiro Tanaka, Masaomi Nangaku. Hypoxia-inducible lncRNA MIR210HG promotes HIF1α expression by inhibiting miR-93-5p in renal tubular cells. The FEBS journal. 2023. 290. 16. 4040-4056
- Yu Kurata, Masaomi Nangaku. Dapagliflozin for the treatment of chronic kidney disease. Expert review of endocrinology & metabolism. 2022. 17. 4. 275-291
- Yu Kurata, Tetsuhiro Tanaka, Hana Cernecka, Frank Eitner, Masaomi Nangaku. TRPM2 Plays a Minor Role in AKI and Kidney Fibrosis. Kidney360. 2022. 3. 1. 153-157
- Yu Kurata, Tetsuhiro Tanaka, Masaomi Nangaku. An evaluation of roxadustat for the treatment of anemia associated with chronic kidney disease. Expert opinion on pharmacotherapy. 2022. 23. 1. 19-28
- Yu Kurata, Tetsuhiro Tanaka, Masaomi Nangaku. The role of hypoxia in the pathogenesis of lupus nephritis. Kidney international. 2020. 98. 4. 821-823
- Yu Kurata, Tetsuhiro Tanaka, Masaomi Nangaku. Hypoxia-inducible factor prolyl hydroxylase inhibitor in the treatment of anemia in chronic kidney disease. Current opinion in nephrology and hypertension. 2020. 29. 4. 414-422
- Yu Kurata, Tetsuhiro Tanaka, Masaomi Nangaku. Prolyl hydroxylase domain inhibitors: a new era in the management of renal anemia. Annals of translational medicine. 2019. 7. Suppl 8. S334
- Mari Aoe, Takafumi Kanemitsu, Takamasa Ohki, Satoru Kishi, Yoshiyasu Ogura, Yuto Takenaka, Toyohiro Hashiba, Hiroko Ambe, Emi Furukawa, Yu Kurata, et al. Incidence and risk factors of contrast-induced nephropathy after transcatheter arterial chemoembolization in hepatocellular carcinoma. Clinical and experimental nephrology. 2019. 23. 9. 1141-1146
- Yasuna Nakamura, Yu Kurata, Yoshifumi Hamasaki, Masaomi Nangaku. Extraperitoneal Placement of a Peritoneal Dialysis Catheter. Internal medicine (Tokyo, Japan). 2019. 58. 1. 147-148
- Tomoko Honda, Satoru Kishi, Emi Furukawa, Hiroko Ambe, Yu Kurata, Masahiro Ichikawa, Mari Aoe, Ken Ohara, Satoshi Furuse, Katsunori Saito, et al. Eicosapentaenoic Acid and Prevalence of Cardiovascular Disease in Hemodialysis Patients. Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy. 2018. 22. 5. 514-518
- Masanori Kurihara, Yu Kurata, Izumi Sugimoto, Yuki Hatanaka, Yasuhisa Sakurai. High PR3-ANCA positivity in a patient with chronic inflammatory demyelinating polyneuropathy. eNeurologicalSci. 2017. 6. 4-5
前のページに戻る